Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 15/20 | 0.83 |
| ▸ | PLG | P00747 | 4/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553010 | 0.95 | CHEK2 (0.83) | CHEK2PLGPLAU | |
| SCHEMBL1552348 | 0.90 | CHEK2 (0.67) | CHEK2PLGPLAU | |
| SCHEMBL1551735 | 0.87 | CHEK2 (0.85) | CHEK2PLGPLAU | |
| SCHEMBL1663387 | 0.85 | CHEK2 (0.66) | CHEK2PLGPLAU | |
| SCHEMBL20982723 | 0.84 | CHEK2 (0.61) | CHEK2PLGPLAU | |
| SCHEMBL16329639 | 0.84 | CHEK2 (0.65) | CHEK2PLGPLAU | |
| SCHEMBL1553016 | 0.84 | CHEK2 (0.86) | CHEK2 | |
| SCHEMBL13305839 | 0.83 | PLG (0.60) | CHEK2PLGPLAU | |
| SCHEMBL3926156 | 0.83 | CHEK2 (0.81) | CHEK2 | |
| SCHEMBL1551751 | 0.82 | CHEK2 (0.85) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | claimed |
| EP-1824832-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | claimed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | claimed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | claimed |
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | disclosed |
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | disclosed |
| EP-1824832-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | WEE1, CDKN1A, DDB1 | CHEK2 27/4885PLG 4788/4885PLAU 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.